Roche Says Phase III Celestimo Study Hits Primary Endpoint
Roche said its Phase III Celestimo study met the primary endpoint in follicular lymphoma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Roche says CELESTIMO phase III met primary endpoint
Roche said its phase III CELESTIMO study met its primary endpoint, with Lunsumio plus lenalidomide improving progression-free survival versus rituximab plus lenalidomide in relapsed/refractory follicular lymphoma. Overall survival data were immature and no new safety signals were reported.